Novo Nordisk(US:NVO) Xin Lang Cai Jing·2026-02-09 21:06Core Viewpoint - The FDA has accused Novo Nordisk of making "false or misleading" claims in television advertisements for its weight loss drug Wegovy, requiring immediate corrective action [2][7]. Group 1: FDA's Concerns - The FDA's letter dated February 5 highlighted that the advertisement misrepresented the oral drug, violating federal law, and demanded the cessation of all misleading advertisements [2][7]. - The FDA pointed out that the advertisement misleadingly suggested that Wegovy's effects were superior to other approved GLP-1 weight loss drugs, using phrases like "live lighter" and "a new way out" without supporting evidence [8]. - The FDA criticized the advertisement for implying that the drug could provide benefits beyond weight loss, such as emotional relief and life direction, which were not substantiated [8]. Group 2: Novo Nordisk's Response and Market Context - Novo Nordisk confirmed receipt of the FDA's letter and stated that the advertisement had been airing since the launch of the tablet, clarifying it was not part of their Super Bowl ad campaign [2][7]. - The company is actively trying to regain market share in the competitive GLP-1 market, facing challenges from major competitors and cheaper generic alternatives [3]. - Wegovy, the company's core product, became the first approved oral GLP-1 weight loss drug globally in January, with over 170,000 patients in the U.S. currently using it [3][7]. Group 3: Legal Actions - On the same day, Novo Nordisk filed a lawsuit against telehealth company Hims & Hers, seeking to prohibit the large-scale sale of a compounded version of Wegovy tablets and injections [4][8].